The effect of phenobarbital on the methylation level of the p16 promoter region in rat liver.
It has been suggested that non-genotoxic carcinogens (NGCs) may cause modification of the DNA methylation status. We studied the effects of phenobarbital (PB) -- a non-genotoxic rodent liver carcinogen -- on the methylation level of the promoter region of the p16 suppressor gene, as well as on hepatomegaly, DNA synthesis, and DNA-methyltransferase (DNMTs) activity in the rat liver. Male Wistar rats received PB in 1, 3 or 14 daily oral doses (at 24-h intervals), each equivalent to 1/10 of the LD(50) value. The study showed that PB has caused persistent elevation in relative liver weight (RLW) as well as a transient increase in DNA synthesis. This suggests that the PB-induced increase in RLW was due to a combination of both hyperplasia and hypertrophy of liver cells. The effect of PB on DNA synthesis corresponded to an increase in the methylation pattern of the p16 promoter sequence. Methylation of cytosine in the analyzed CpG sites of the p16 gene was found after short exposure of the animals to PB. Treatment of rats with PB for 1 and 3 days also produced an increase in nuclear DNMTs activity. After prolonged administration (14 days), DNA synthesis declined, returning to the control level. No changes in methylation of the p16 gene nor in DNMTs activity were observed. The reversibility of early induced changes in target tissues is a mark characteristic of tumor promoters. Thus, transient changes in methylation of the p16 gene, although their direct role in the mechanisms of PB toxicity, including its carcinogenic action, remains doubtful, may therefore be a significant element of such processes.
Kostka
Grazyna
G
Department of Environmental Toxicology, National Institute of Hygiene, Chocimska 24, 00-791, Warsaw, Poland. gkostka@pzh.gov.pl
Urbanek
Katarzyna
K
Ludwicki
Jan K
JK
D000284:Administration, Oral; D000818:Animals; D000927:Anticonvulsants / Q000633:toxicity*; D002273:Carcinogens / Q000633:toxicity*; D018899:CpG Islands / Q000187:drug effects; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D019175:DNA Methylation; D004261:DNA Replication / Q000187:drug effects; D019942:Genes, p16 / Q000187:drug effects*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010634:Phenobarbital / Q000633:toxicity*; D011401:Promoter Regions, Genetic / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar
D000927:Anticonvulsants; D002273:Carcinogens; D019941:Cyclin-Dependent Kinase Inhibitor p16; D010634:Phenobarbital